Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Quality of Life Study of PEGASYS® (Peginterferon-Alfa2a) in Combination With COPEGUS® (Ribavirin) in Patients With Chronic Hepatitis C and Persistently Normal ALT Levels

NCT02726022 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT02726022
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02726022 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Quality of Life Study of PEGASYS® (Peginterferon-Alfa2a) in Combination With COPEGUS® (Ribavirin) in Patients With Chronic Hepatitis C and Persistently Normal ALT Levels
Lead sponsor
Hoffmann-La Roche
Phase
Observational
Overall status
Completed
Start date
February 28, 2007
Completion date
July 31, 2011
Enrollment
114 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c, chronic